Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLL018 in Moderate-to-Severe Plaque Psoriasis
NCT05772520Phase 2Completed
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd.
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of girocitinib in plaque psoriasis (3 cohorts), sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd. Primary endpoint: Proportion of Participants Achieving Psoriasis Area and Severity Index 75 at 12 weeks. Started Jan 2023; status: completed.
02
Drugs
girocitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05772520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05772520.